Calcimedica to participate in the h.c. wainwright 4th annual kidney virtual conference

La jolla, calif. , july 8, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that rachel leheny, ph.d.
CALC Ratings Summary
CALC Quant Ranking